Profile data is unavailable for this security.
About the company
Invizyne Technologies, Inc. is a biotechnology, pre-revenue, development stage company. The Company's cell-free technology expands its ability to perform enzyme-based conversions, guiding towards sustainable biomanufacturing. The Company is primarily engaged in the development of the SimplePath platform. Its SimplePath platform consists of a series of enzyme based biomanufacturing systems that leverage natural processes to perform complex chemical conversions that convert a starting material into a desired end-product. Each SimplePath system is composed of one or more modules which consist of one or more enzymes that work together to perform a defined biocatalytic conversion. It can provide solutions for natural ingredients (cannabinoids, flavor enhancers for food and beverage products, fragrances, nutraceuticals, organic compounds), pharmaceuticals (natural products with therapeutic properties) and chemicals (commodity chemicals, specialty chemicals, biofuels).
- Revenue in USD (TTM)0.00
- Net income in USD-5.12m
- Incorporated2019
- Employees31.00
- LocationInvizyne Technologies Inc750 Royal Oaks Drive, Suite 106MONROVIA 91016United StatesUSA
- Phone+1 (626) 415-1488
- Websitehttps://www.invizyne.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rani Therapeutics Holdings Inc | 0.00 | -28.17m | 111.50m | 140.00 | -- | 35.95 | -- | -- | -1.06 | -1.06 | 0.00 | 0.0579 | 0.00 | -- | -- | 0.00 | -96.37 | -- | -165.17 | -- | -- | -- | -- | -- | -- | -16.57 | 0.8306 | -- | -- | -- | -11.06 | -- | -- | -- |
| Pyxis Oncology Inc | 16.15m | -57.36m | 112.98m | 54.00 | -- | 0.735 | -- | 7.00 | -1.05 | -1.05 | 0.2977 | 2.59 | 0.0845 | -- | -- | 322,920.00 | -30.03 | -- | -34.41 | -- | 97.06 | -- | -355.24 | -- | -- | -- | 0.0008 | -- | -- | -- | 38.87 | -- | -- | -- |
| Alto Neuroscience Inc | 0.00 | -57.45m | 116.19m | 88.00 | -- | 0.7042 | -- | -- | -2.42 | -2.42 | 0.00 | 6.12 | 0.00 | -- | -- | 0.00 | -46.93 | -- | -51.10 | -- | -- | -- | -- | -- | -- | -- | 0.0649 | -- | -- | -- | -31.02 | -- | -- | -- |
| Outlook Therapeutics Inc | 0.00 | -94.05m | 118.99m | 24.00 | -- | -- | -- | -- | -8.12 | -8.12 | 0.00 | -3.57 | 0.00 | -- | -- | 0.00 | -205.48 | -214.69 | -- | -1,843.48 | -- | -- | -- | -3,043.92 | -- | -26.89 | -- | -- | -- | -- | 10.70 | -- | -- | -- |
| Repare Therapeutics Inc | 66.52m | -84.05m | 119.46m | 179.00 | -- | 0.6828 | -- | 1.80 | -2.00 | -2.00 | 1.56 | 4.12 | 0.270 | -- | 3.95 | 371,642.50 | -34.11 | -23.40 | -40.73 | -26.37 | -- | -- | -126.34 | -162.76 | -- | -- | 0.00 | -- | -61.21 | -- | -222.91 | -- | 27.16 | -- |
| Invizyne Technologies Inc | 0.00 | -5.12m | 121.10m | 31.00 | -- | -- | -- | -- | -0.6305 | -0.6305 | 0.00 | -0.4431 | 0.00 | -- | -- | 0.00 | -146.70 | -- | -- | -- | -- | -- | -- | -- | -- | -66.29 | -- | -- | -- | -- | -46.00 | -- | -- | -- |
| Skye Bioscience Inc | 0.00 | -21.24m | 124.99m | 11.00 | -- | 1.65 | -- | -- | -0.8405 | -0.8405 | 0.00 | 2.50 | 0.00 | -- | -- | 0.00 | -43.73 | -232.67 | -54.60 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -93.23 | -- | 23.38 | -- |
| Cardiff Oncology Inc | 689.00k | -43.01m | 125.28m | 31.00 | -- | 2.42 | -- | 181.83 | -0.9493 | -0.9493 | 0.0152 | 1.01 | 0.0091 | -- | 1.69 | 22,225.81 | -56.80 | -31.24 | -66.22 | -33.56 | -- | -- | -6,238.17 | -7,819.23 | -- | -- | 0.00 | -- | 26.42 | 5.22 | -7.07 | -- | 157.91 | -- |
| Coherus Biosciences Inc | 304.34m | -450.00k | 125.58m | 235.00 | -- | -- | 25.86 | 0.4126 | -0.0892 | -0.0892 | 2.60 | -0.7636 | 0.5591 | 2.94 | 1.58 | 994,575.20 | -0.0827 | -21.43 | -0.1626 | -29.32 | 44.71 | 79.01 | -0.1479 | -36.56 | 1.09 | -3.92 | 1.50 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
| Adverum Biotechnologies Inc | 1.00m | -94.11m | 125.65m | 121.00 | -- | 0.8718 | -- | 125.65 | -6.03 | -6.03 | 0.0585 | 6.93 | 0.0046 | -- | -- | 8,264.46 | -43.66 | -36.39 | -50.24 | -39.04 | -- | -- | -9,411.10 | -5,279.60 | -- | -- | 0.00 | -- | -- | 17.43 | 24.18 | -- | -0.0247 | -- |
| Vigil Neuroscience Inc | 0.00 | -82.60m | 130.41m | 66.00 | -- | 1.43 | -- | -- | -2.07 | -2.07 | 0.00 | 2.23 | 0.00 | -- | -- | 0.00 | -56.88 | -- | -66.15 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.98 | -- | -- | -- |
| Ventyx Biosciences Inc | 0.00 | -152.52m | 130.81m | 75.00 | -- | 0.469 | -- | -- | -2.37 | -2.37 | 0.00 | 3.94 | 0.00 | -- | -- | 0.00 | -48.98 | -- | -52.21 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.97 | -- | -- | -- |
